Aimmune Therapeutics (AIMT) Now Covered by Analysts at Piper Jaffray

Piper Jaffray assumed coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note published on Friday. The firm issued an overweight rating and a $30.01 price target on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the company. Deutsche Bank set a $30.00 price objective on Aimmune Therapeutics and gave the stock a buy rating in a report on Tuesday, February 20th. Credit Suisse Group set a $45.00 target price on Aimmune Therapeutics and gave the stock a buy rating in a research report on Tuesday, February 20th. Cantor Fitzgerald reissued a buy rating on shares of Aimmune Therapeutics in a research report on Tuesday, February 20th. Roth Capital raised their target price on Aimmune Therapeutics from $60.00 to $75.00 and gave the stock a buy rating in a research report on Wednesday, January 31st. Finally, Wedbush reissued a buy rating on shares of Aimmune Therapeutics in a research report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $53.67.

Aimmune Therapeutics traded up $1.29, hitting $31.30, during trading hours on Friday, according to MarketBeat.com. The company’s stock had a trading volume of 866,949 shares, compared to its average volume of 409,772. Aimmune Therapeutics has a 12 month low of $15.97 and a 12 month high of $42.00. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -11.99 and a beta of -0.36.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.21). During the same period in the prior year, the company posted ($0.52) earnings per share. equities research analysts anticipate that Aimmune Therapeutics will post -2.81 EPS for the current year.

In other news, Director Patrick G. Enright bought 15,593 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were acquired at an average cost of $32.00 per share, with a total value of $498,976.00. Following the completion of the transaction, the director now owns 22,869 shares of the company’s stock, valued at approximately $731,808. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Bakker Juliet Tammenoms bought 9,375 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was purchased at an average cost of $32.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now directly owns 16,651 shares of the company’s stock, valued at approximately $532,832. The disclosure for this purchase can be found here. Insiders acquired 58,093 shares of company stock worth $1,858,976 over the last three months. Insiders own 24.56% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. First Republic Investment Management Inc. purchased a new position in shares of Aimmune Therapeutics during the 4th quarter valued at about $202,000. Virtu Financial LLC purchased a new position in shares of Aimmune Therapeutics during the 4th quarter valued at about $239,000. Xact Kapitalforvaltning AB purchased a new position in shares of Aimmune Therapeutics during the 1st quarter valued at about $207,000. Teacher Retirement System of Texas purchased a new position in shares of Aimmune Therapeutics during the 4th quarter valued at about $282,000. Finally, Wedbush Securities Inc. purchased a new position in shares of Aimmune Therapeutics during the 1st quarter valued at about $292,000. 66.79% of the stock is currently owned by hedge funds and other institutional investors.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply